## Deloitte.

India | Tax & Regulatory | 4 December 2015



# Global Business Tax Alert Sharp Insights

Delhi Tribunal allows claim of expenditure on free samples given to doctors/ medical practitioners Issue no: GBTA/80/2015

In this issue:

Upcoming Dbriefs - Register Contacts

The Delhi Tribunal in the case of Eli Lilly & Co. (India) Pvt. Ltd. v ACIT [TS-680-ITAT-2015(DEL)] has allowed a claim of expenditure incurred on free samples given to doctors/medical practitioners<sup>1</sup>.

The assessee, engaged in the business of trading of formulations and marketing and selling of life saving drugs formulations, had incurred expenses towards distribution of free samples to doctors/medical practitioners.

The expenses towards distribution of free samples were disallowed by the Assessing Officer (AO) in view of CBDT Circular No. 5/2012 dated 01.08.2012 (Circular). The Circular had stated that the Indian Medical Council (IMC), *vide* the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, had imposed a prohibition on the medical practitioners and their professional associations from taking any gift, travel facility, hospitality, cash or monetary grant from the pharmaceutical and allied health sector industries. Accordingly, the AO held such expenses being prohibited by the law were not allowable under the Income-tax Act, 1961 (Act).

Before the Tribunal, the assessee contended that that such samples could not, in any manner, be said to be covered within the ambit of the term 'gift', much less conferring any benefit to such

doctors/ medical practitioners. The assessee contended that samples were distributed upon specific request being made by the practitioners and were not distributed voluntarily so as to influence the doctor's discretion of prescribing medicines to the patients. Moreover, such samples were used by the patients of the doctors and not by the doctor himself. With additional reference to IMC Regulations, the assessee argued that only freebies which conferred personal benefit to the medical practitioner directly could be considered in violation of the Medical Council's guidelines. Reference was also drawn from a Circular issued by Ministry of Chemicals & Fertilizers and the Drugs, Department of Pharmaceuticals and the provisions of Drugs and Cosmetics Act, 1945 which permitted distribution of free samples on fulfillment of certain conditions.

The assessee also placed reliance on the order of the Dispute Resolution Panel (DRP) for the immediately preceding assessment year which had permitted a deduction for such expenses.

<sup>&</sup>lt;sup>1</sup> We have not analysed any other issue covered in the appeal

The Tribunal, acknowledging that the order of the DRP for earlier assessment year had not been appealed by the tax authorities and applying the principle of consistency, allowed the deduction on expenses incurred on free samples. The Tribunal had also accepted the reliance of the DRP on the decision of the Supreme Court in the case of Eskayef Pharmaceuticals wherein it was explained that sample drugs are distributed in order to create awareness and thus same cannot be equated with publicity and sales promotion.


It may be noted that the validity of the Circular had been upheld by the Himachal Pradesh High Court in the case of Confederation of Indian Pharmaceutical Industry v. UOI. While upholding the validity, the High Court had also held that where the assesse satisfies the AO that the expenditure is not in violation of the Medical Council Regulations, the assesse may legitimately claim a deduction.

# Upcoming Dbriefs – Register

**BEPS: Implementation of Transfer Pricing Changes (Part 2: India and Southeast Asia)** 

On 8 December 2015 from 11:30 AM to 12:30 PM IST

As the OECD / G20 BEPS project has moved into the implementation phase, we will provide an update of domestic legislative activities and timelines to incorporate the various BEPS transfer pricing changes into specific domestic tax regimes. We will also cover harmonization efforts for transfer pricing documentation rules and requirements from local perspectives. In this Part 2 webcast, our focus will be on India and Southeast Asia. For more information, visit the <a href="Dbriefs">Dbriefs</a> page



Register Now

### Contacts

#### **Ahmedabad**

Heritage, 3rd Floor, Near Gujarat Vidyapith, Off Ashram Road, Ahmedabad – 380 014. Tel: + 91 (079) 2758 2542

Fax: + 91 (079) 2758 2551

#### Coimbatore

Shanmugha Manram 41, Race Course, Coimbatore Tamil Nadu - 641018 Tel: + 91 (0422) 439 2801 Fax: +91 (0422) 222 3615

#### Kolkata

Bengal Intelligent Park Building Alpha, 1st floor, Block EP and GP Sector V, Salt Lake Electronics Complex, Kolkata - 700 091.

Tel: +91 (033) 6612 1000 Fax: +91 (033) 6612 1001

#### **Bangalore**

Deloitte Centre, Anchorage II, 100/2, Richmond Road, Bangalore 560 025. Tel: +91 (080) 6627 6000 Fax: +91 (080) 6627 6010

#### Delhi/Gurgaon

Building 10, Tower B, 7th Floor, DLF Cyber City, Gurgaon 122 002 Tel: +91 (0124) 679 2000

Fax: +91 (0124) 679 2012

#### Mumbai

Indiabulls Finance Centre, Tower 3, 28th Floor, Elphinstone Mill Compound, Senapati Bapat Marg, Elphinstone (W), Mumbai – 400013

Tel: + 91 (022) 6185 4000 Fax: + 91 (022) 6185 4101

#### Chennai

No.52, Venkatanarayana Road, 7th Floor, ASV N Ramana Tower, T-Nagar, Chennai 600 017.

Tel: +91 (044) 6688 5000 Fax: +91 (044) 6688 5050

#### Hyderabad

1-8-384 and 385, 3rd Floor, Gowra Grand S.P.Road, Begumpet, Secunderabad – 500 003. Tel: +91 (040) 6603 2600 Fax:+91 (040) 6603 2714

#### **Pune**

106, B-Wing, 7<sup>th</sup> Floor, ICC Trade Tower, Senapati Bapat Road, Pune – 411 016. Tel: + 91 (020) 6624 4600

Fax: +91 (020) 6624 4605

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. Please see <a href="https://www.deloitte.com/about">www.deloitte.com/about</a> for a more detailed description of DTTL and its member firms.

This material and the information contained herein prepared by Deloitte Touche Tohmatsu India LLP (DTTI LLP) is intended to provide general information on a particular subject or subjects and is not an exhaustive treatment of such subject(s). This material contains information sourced from third party sites (external sites). DTTI LLP is not responsible for any loss whatsoever caused due to reliance placed on information sourced from such external sites. None of DTTI LLP, Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively, the "Deloitte Network") is, by means of this material, rendering professional advice or services. This information is not intended to be relied upon as the sole basis for any decision which may affect you or your business. Before making any decision or taking any action that might affect your personal finances or business, you should consult a qualified professional adviser.

No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this material.

©2015 Deloitte Touche Tohmatsu India LLP. Member of Deloitte Touche Tohmatsu Limited

Registered office: 12, Dr. Annie Besant Road, Opp. Shiv Sagar Estate, Worli, Mumbai – 400 018, India. Deloitte Touche Tohmatsu India Private Limited (U74140MH1995PTC093339), a private company limited by shares, was converted into Deloitte Touche Tohmatsu India LLP (LLP Identification No. AAE- 8458), a limited liability partnership, with effect from October 1, 2015.

Home | Add Deloitte as a safe sender

Follow us on:







